Navigation Links
Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
Date:5/3/2011

GLEN BURNIE, Md., May 3, 2011 /PRNewswire/ -- Answering the need for global, site-focused enrollment support, Clinical Site Services (CSS), a leader in the patient enrollment industry, announces the expansion of its services to include global enrollment planning and implementation on a local, site-centric level.

"The extension of our worldwide presence is an important step that will allow us to assist sponsors with their global patient enrollment needs," says Chris Trizna, President of Clinical Site Services. "To date, we have been quite successful in delivering patient enrollment solutions to investigative sites and sponsors in North America; this expansion means that sponsors no longer need to seek out different patient recruitment partners for North American and Rest-of-World needs."

The CSS London-based office, headed up by industry executive Richard Anderson, will tap into professionals who have more than 20 years of experience in the life science, healthcare and patient recruitment industries. They will be able to implement patient enrollment and retention campaigns which are solely based in global markets, or as an adjunct to North American endeavors.

As with all CSS North American campaigns, the global programs will offer customized clinical research support and expertise. Through Local Enrollment Specialists, regional experts who have detailed knowledge of each country's regulatory provisions, CSS will provide site assessments, chart reviews, ethics committee submissions, local patient enrollment expertise, planning and implementation in more than 40 countries.

"This is an exciting new initiative. For the first time a patient enrollment provider can support sites at local level in over 40 countries," stated Richard Anderson, CSS Director of Global Patient Enrollment. "The teams will be working with the sites to help optimize their patient enrollment programs, maximizing enrollment and ROI."

All international endeavors will be centrally managed by CSS's project team.

"It all comes down to enrollment. Generating interest is important, but it's what happens after that," shared Trizna. "Sites are the only ones who can enroll patients. Successful sites consistently meet their enrollment goals. We are poised to support them with enrollment planning and implementation."

About Clinical Site Services

Founded in 2005, Clinical Site Services (CSS) is a global enrollment performance company that increases enrollment and retention for pharma, CROs and investigative sites through a site-focused approach and adaptive enrollment process.

US Contact:
Jennifer Whitlock
VP/Director of Marketing
Clinical Site Services
P: 410-793-1067
F: 410-553-0087
jwhitlock@clinicalsiteservices.com
http://www.ClinicalSiteServices.com

UK Contact:
Richard Anderson
Director of Global Patient Enrollment
Clinical Site Services
P: +44 020 8347 9935
randerson@clinicalsiteservices.com
http://www.ClinicalSiteServices.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Clinical Site Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Omnicare Clinical Research Acquired by Nautic Partners, LLC
3. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
4. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
9. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
10. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
11. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power ... triple negative breast cancer (TNBC), announced today their completion of ... The YEi Start in France ... their business in France and Europe.  ... complete an intensive one week immersion in France ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):